P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer
Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is...
Main Authors: | Hira Lal Goel, Bryan Pursell, Leonard D. Shultz, Dale L. Greiner, Rolf A. Brekken, Craig W. Vander Kooi, Arthur M. Mercurio |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-03-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124716301024 |
Similar Items
-
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
by: Michael T Dellinger, et al.
Published: (2011-01-01) -
Regulated Splicing of the α6 Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells
by: Hira Lal Goel, et al.
Published: (2014-05-01) -
Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (<em>Spermophilus dauricus</em>)
by: Yuchen Yao, et al.
Published: (2021-03-01) -
Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
by: Wang M, et al.
Published: (2019-06-01) -
Targeting VEGF/VEGFR to Modulate Antitumor Immunity
by: Ju Yang, et al.
Published: (2018-05-01)